Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Revenue (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Revenue for 5 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 36.87% to $57.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $189.8 million, a 45.83% increase, with the full-year FY2025 number at $189.8 million, up 45.83% from a year prior.
  • Revenue was $57.3 million for Q4 2025 at Rhythm Pharmaceuticals, up from $51.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $57.3 million in Q4 2025 to a low of -$8.0 million in Q4 2022.
  • A 5-year average of $20.0 million and a median of $20.9 million in 2023 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 4180.0% in 2022; the steepest drop was 542.93% in 2022.
  • Rhythm Pharmaceuticals' Revenue stood at $1.8 million in 2021, then tumbled by 542.93% to -$8.0 million in 2022, then soared by 401.12% to $24.2 million in 2023, then soared by 72.61% to $41.8 million in 2024, then surged by 36.87% to $57.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Revenue are $57.3 million (Q4 2025), $51.3 million (Q3 2025), and $48.5 million (Q2 2025).